Smoking impairs bradykinin-stimulated t-PA release
- PMID: 11897760
- DOI: 10.1161/hy0302.105767
Smoking impairs bradykinin-stimulated t-PA release
Abstract
Bradykinin stimulates tissue plasminogen activator release from human endothelium through a flow-independent, B2 receptor-dependent mechanism. The present study tests the hypothesis that smoking impairs bradykinin-stimulated tissue plasminogen activator release. Graded doses of nitroprusside (1.6 to 6.4 microg/min), methacholine (3.2 to 12.8 microg/min), and bradykinin (100 to 400 ng/min) were infused in the brachial artery in random order in 20 smokers and 12 nonsmokers matched for age, gender, and body mass index. Forearm blood flow was measured by strain-gauge plethysmography. All 3 drugs caused a dose-dependent increase in forearm blood flow, with no significant difference between smokers and nonsmokers. Bradykinin (P=0.001) and methacholine (P=0.001) caused significant dose-dependent increases in net tissue plasminogen activator release. The tissue plasminogen activator response to bradykinin was significantly greater than the tissue plasminogen activator response to methacholine in the nonsmokers (maximal net tissue plasminogen activator release, 73.2+/-21.5 versus 27.6+/-7.2 ng/min per 100 mL; P=0.001) but not in the smokers (maximal net tissue plasminogen activator release, 44.5+/-10.7 versus 24.8+/-9.3 ng/min per 100 mL; P=0.154). The effect of bradykinin (P=0.037), but not methacholine (P=0.978), on net tissue plasminogen activator release was significantly reduced in smokers compared with nonsmokers. The vascular tissue plasminogen activator response to bradykinin, but not methacholine, is impaired in smokers. Stimulated tissue plasminogen activator release may be a more sensitive measure of endothelial function than vasodilation.
Similar articles
-
Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin.Circulation. 2003 Feb 4;107(4):579-85. doi: 10.1161/01.cir.0000046268.59922.a4. Circulation. 2003. PMID: 12566370 Clinical Trial.
-
Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium-independent agonists in human vasculature.J Am Coll Cardiol. 1998 Jul;32(1):117-22. doi: 10.1016/s0735-1097(98)00210-1. J Am Coll Cardiol. 1998. PMID: 9669258
-
Bradykinin stimulates tissue plasminogen activator release in human vasculature.Hypertension. 1999 Jun;33(6):1431-5. doi: 10.1161/01.hyp.33.6.1431. Hypertension. 1999. PMID: 10373228
-
Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition.J Am Coll Cardiol. 2001 Nov 1;38(5):1402-8. doi: 10.1016/s0735-1097(01)01562-5. J Am Coll Cardiol. 2001. PMID: 11691515 Clinical Trial.
-
Marked impairment of protease-activated receptor type 1-mediated vasodilation and fibrinolysis in cigarette smokers: smoking, thrombin, and vascular responses in vivo.J Am Coll Cardiol. 2008 Jul 1;52(1):33-9. doi: 10.1016/j.jacc.2008.04.003. J Am Coll Cardiol. 2008. PMID: 18582632
Cited by
-
Contribution of endogenous bradykinin to fibrinolysis, inflammation, and blood product transfusion following cardiac surgery: a randomized clinical trial.Clin Pharmacol Ther. 2013 Apr;93(4):326-34. doi: 10.1038/clpt.2012.249. Epub 2012 Dec 24. Clin Pharmacol Ther. 2013. PMID: 23361105 Free PMC article. Clinical Trial.
-
Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis.J Am Soc Nephrol. 2012 Feb;23(2):334-42. doi: 10.1681/ASN.2011030287. Epub 2011 Dec 8. J Am Soc Nephrol. 2012. PMID: 22158433 Free PMC article. Clinical Trial.
-
Effects of ageing and regular aerobic exercise on endothelial fibrinolytic capacity in humans.J Physiol. 2003 Jan 1;546(Pt 1):289-98. doi: 10.1113/jphysiol.2002.027870. J Physiol. 2003. PMID: 12509496 Free PMC article.
-
Effect of smoking on age at the time of coronary artery bypass graft surgery; baseline data results from the ROSETTA-CABG registry.Heart Asia. 2010 Jul 21;2(1):48-51. doi: 10.1136/ha.2009.001586. eCollection 2010. Heart Asia. 2010. PMID: 27325942 Free PMC article.
-
Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease.Heart. 2006 Feb;92(2):170-6. doi: 10.1136/hrt.2004.059683. Epub 2005 Apr 29. Heart. 2006. PMID: 15863522 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources